or
forgot password

Genetic Investigation of Solid Tumors Cohort


N/A
18 Years
N/A
Open (Enrolling)
Both
Prostate Cancer, Colon Cancer

Thank you

Trial Information

Genetic Investigation of Solid Tumors Cohort


Recent studies in human genetics have discovered several intervals in the human genome
containing inherited variants that are statistically associated with the propensity to
develop solid tumors. Even though it has been firmly established that if an individual
carries these DNA variants they have an increased chance of developing a solid tumor the
underlying biological mechanisms for most of these associations are largely unknown.

In addition to inherited DNA variants that are associated with the development of solid
tumors it is well established that during the development and growth of solid tumors the DNA
in these cancer cells undergo somatic changes (mutations). These somatic DNA changes have
been studied over the past decade and frequently are specific chromosomal translocations and
amplifications associated with the development of particular solid tumors. In some
instances, examining the chromosomal translocation and amplification has lead to the
discovery of proteins contributing to solid tumor pathology.

the human 8q24 interval that has strong genetic associations with solid tumor development
has also been noted as frequently amplified in solid tumors and serves as a predictor of
poor survival in prostate cancers.


Inclusion Criteria:



1. Age 18 years or older

2. Eligible to have their blood drawn

3. Be reliable, cooperative and willing to comply with all protocol-specified procedures

4. Able to understand and grant informed consent

5. Diagnosis of a solid tumor

Exclusion Criteria:

1. Has a significant chronic medical condition which would potentially confound
interpretation of the individual's phenotype.

2. Treatment with any investigational agents or devices within thirty days preceding
enrollment in the study.

3. Been administered or taken any CNS sedatives or depressants in the 12 hours prior to
informed consent process

Type of Study:

Observational

Study Design:

Observational Model: Cohort

Outcome Measure:

Solid tumor biological insights

Outcome Description:

Obtain blood samples, solid tumor and/or benign hyperplasia samples, and in some instances normal tissue in order to gain biological insights into cancer (solid tumors) through population genetics and genomics.

Outcome Time Frame:

Study completion

Safety Issue:

No

Principal Investigator

James Mason, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Scripps Health

Authority:

United States: Institutional Review Board

Study ID:

HSC# 004835

NCT ID:

NCT01005225

Start Date:

February 2008

Completion Date:

December 2014

Related Keywords:

  • Prostate Cancer
  • Colon Cancer
  • Solid tumor
  • prostate cancer
  • colon cancer
  • Colonic Neoplasms
  • Prostatic Neoplasms

Name

Location

Scripps Health San Diego, California  92037